Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine Teva in Symptomatic Sickle Cell Disease
NCT03247218Phase 2Unknown
- Sponsor
- Emek Medical Center
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of memantine in sickle cell disease (SCD), sponsored by Emek Medical Center. Status: unknown.
02
Drugs
memantine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03247218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247218.